source
- Arrowhead reports Phase 3 data showing potentially best-in-class triglyceride reduction, eyes FDA filingArrowhead Pharmaceuticals announced topline results from two late-stage Phase 3 trials (SHASTA-3 and SHASTA-4) of its siRNA drug plozasiran in patients with severe hypertriglyceridemia (sHTG). Th…
- Mentari Therapeutics secures second $200M private placement to fund migraine program and advance reverse mergerMentari Therapeutics, a spin‑out focused on migraine treatments, announced it has arranged a second private‑placement financing of $200 million. The new capital will be used to advance its migrain…Endpoints · 23d agoDealPositive